Overview

Op2lysis is a private French biotechnology company focused on developing innovative therapies for neurological disorders caused by blood clots. Specializing in thrombolytic treatments, Op2lysis aims to advance healthcare in acute ischemic stroke through cutting-edge research and development.

Therapeutic areas

NeurologyThrombolysisStroke

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Op2lysis in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.

For suppliers

Is this Op2lysis?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.